NeuroNova wants to recharge neurons. The biopharmaceutical company is engaged in the research and development of therapies to help regenerate central nervous system cells in patients with Alzheimer's disease, Parkinson's disease, and other disorders. Its research focuses on developing drugs that will stimulate endogenous stem and progenitor cells to restore damaged areas of the brain. The company has two drug candidates nearing clinical development in addition to other compounds in the discovery and pre-clinical phases. NeuroNova was founded in 1998 and is financed by Swedish venture capital companies HealthCap, Scandinavian Life Science Venture, and Investor Growth Capital.

Catalent Pharma Solutions, Inc. provides proprietary drug delivery and packaging technologies, and outsourced services to pharmaceutical, biotechnology, and consumer healthcare companies worldwide. It operates in three segments: Oral Technologies, Sterile Technologies, and Packaging Services. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products, which are used in various customer products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as tablets and capsules. The Sterile Technologies segment produces various sterile dose forms used in the prescription drug and biologic market.This segment provides formulation and development for injectables, as well as lyophilization for otherwise unstable drugs and biologics. It also fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats; and offers blow-fill-seal technology. In addition, this segment offers biologic cell line development, analytical, and scientific consulting services, as well as provides services for inhaled products. The Packaging Services segment provides various contract packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit-doses; printed components services, such as creating package inserts or folding cartons; and clinical trial supply services providing packaging, and inventory and logistics management for clinical trials. The company has a strategic alliance with Endotis Pharma to develop oral formulations of synthetic oligosaccharides. The company is based in Somerset, New Jersey.

Sanofi-Aventis Deutschland boasts itself as one of the largest pharmaceutical businesses in the country. A subsidiary of French giant Sanofi-Aventis, the company manufactures and markets prescription and over-the-counter drugs. Along with its Lantus and Insuman insulin products, Sanofi-Aventis Deutschland produces Plavix and Lovenox. The company also dedicates much of its efforts on research and development at its Frankfurt, Germany headquarters and is focused on metabolic illnesses such as diabetes, as well as cancer and cardiovascular diseases.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.

Kent International Holdings, Inc. was founded in 1982 and is based in Far Hills, New Jersey. Kent International Holdings, Inc. (Kent International), formerly Cortech, Inc. was a biopharmaceutical company whose primary focus had been the discovery and development of therapeutics for the treatment of inflammatory disorders. It had directed its research and development efforts principally toward protease inhibitors and bradykinin antagonists. The Company has not identified the particular business, which it will seek to engage, nor has it conducted any market studies with respect to any business or industry to evaluate the possible merits or risks of the target business or industry, which the Company ultimately may operate.

ARYx Therapeutics, Inc. was incorporated in 1997 and is based in Fremont, California. ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; budiodarone/ATI-2042, an oral antiarrhythmic agent in Phase II clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat; ATI-7505, an oral prokinetic agent in Phase II clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. The company also involves in the preclinical development of ATI-20,000 and ATI-24,000, which focus on metabolic and gastrointestinal disorders.

Streck, Inc. company was founded in 1971 and is based in Omaha, Nebraska. Streck, Inc. develops and manufactures hematology, chemistry, and immunology products for the clinical laboratory in the United States, Japan, and internationally. It offers controls for automated hematology instruments, and hematology controls, reagents, and support products; controls for immunophenotyping by flow cytometry; A1c-Cellular, a blood cellular control product for instruments measuring HbA1c; and UA-Cellular for IQ that provides a thorough evaluation of the iQ instrument's ability to identify and quantify white blood cells, red blood cells, non-squamous epithelial cells, and crystals. The company also provides hematology reagents, which include diluents, lysing agents, enzymatic cleansers, and detergents; quality control devices, including the red spirit thermometers with scales in 1/2-degree increments to monitor refrigerators, freezers, and incubators/room temperatures; and automated erythrocyte sedimentation rate (ESR) analyzers. In addition, it offers technical services.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

The German drug company -- seller of popular over-the-counter remedies Zantac and Dulcolax, as well as prescription Flomax for enlarged prostate -- makes a host of prescription and OTC products, not to mention fine chemicals and pet medications. Its prescription drugs include treatments for respiratory ailments, hypertension, HIV, and depression. Boehringer also offers cold, gastrointestinal, and pain remedies, as well as vaccines, drugs, and nutritionals for farm animals and pets. The company operates worldwide. The founding Boehringer family controls the company through parent company C.H. Boehringer Sohn.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.